Photodynamic Priming and Minocycline Overcome Chemoresistance by Reprogramming the Pancreatic Tumor Immune Microenvironment In Vivo
T-cell infiltration, reduced regulatory T cells, and M2-like macrophage population. This combination achieved sustained local tumor regression, abscopal effects in untreated distant tumors, and a significant improvement in long-term survival (63%). By integrating clinically approved agents with non-overlapping mechanisms within a light-activated delivery platform, this approach enhances IRI efficacy, reprograms the TME, and promotes antitumor immunity, offering a translatable strategy to sensitize PDAC to chemo- and immunotherapy.
Authors
- Huang‐Chiao Huang (ORCID: https://orcid.org/0000-0002-5406-0733)
- Girgis Obaid (ORCID: https://orcid.org/0000-0002-9452-4467)
- Badri Parshad (ORCID: https://orcid.org/0000-0001-6496-8844)
- Fernanda V. Cabral (ORCID: https://orcid.org/0000-0001-6247-2220)
- Tayyaba G. Hasan (ORCID: https://orcid.org/0000-0003-0871-6057)
- Olivia Mooradian
- Jose Quilez‐Alburquerque
- Shivendran Vytheswarran
Institutions
- Harvard University (US)
- The University of Texas at Dallas (US)
- Massachusetts General Hospital (US)
- Massachusetts Institute of Technology (US)
- University of Maryland, College Park (US)
Publication Details
- Journal
- Advanced Science
- Published
- 2026-04-17
- DOI
- https://doi.org/10.1002/advs.75291
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Science Foundation